Please login to the form below

Not currently logged in
Email:
Password:

muscle disease

This page shows the latest muscle disease news and features for those working in and with pharma, biotech and healthcare.

Novartis buys gene therapy firm AveXis for $8.7bn

Novartis buys gene therapy firm AveXis for $8.7bn

ex-US rights to Spark Therapeutics’recently-approved Luxturna (voretigene neparvovec-rzyl) for an inherited eye disease. ... Last year, Biogen secured approval for the first drug treatment for SMA, a progressive, debilitating muscle-wasting disease

Latest news

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    Trust. Spinraza (nusinersen) became the first drug to be approved for the often-fatal genetic disease, which affects muscle strength and movement, last May but its review by NICE has been ... However, it adds: “there is concern that this route is not

  • Biogen wins European spinal muscular atrophy first Biogen wins European spinal muscular atrophy first

    Biogen now has approval in Europe to go with its US license for Spinraza, its drug for the genetic disease spinal muscular atrophy (SMA). ... cases of the progressive, debilitating muscle-wasting disease.

  • FDA clears new ALS drug Radicava ahead of schedule FDA clears new ALS drug Radicava ahead of schedule

    Patients with the chronic neurodegenerative disease amyotrophic lateral sclerosis (ALS) have a new treatment option in the US after the FDA approved Mitsubishi Tanabe Pharma's Radicava (edaravone). ... ALS is a form of motor neuron disease (MND) which

  • Biogen proffers new data to support high-priced Spinraza Biogen proffers new data to support high-priced Spinraza

    The new results come from the ENDEAR trial, which was halted earlier after showing a clear benefit for Spinraza (nusinersen) over placebo in SMA, an often fatal genetic disease affecting muscle ... Leerink analyst Geoffrey Porges suggested recently the

  • FDA approves Biogen's Spinraza for spinal muscular atrophy FDA approves Biogen's Spinraza for spinal muscular atrophy

    Spinraza (nusinersen) became the first drug to be approved in the US to treat children and adults with SMA - an often fatal genetic disease affecting muscle strength and movement - just ahead ... Their high expectations for the drug are based on lofty

More from news
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo

  • Astellas: Ten years young Astellas: Ten years young

    The two new areas the company has publicly said it will be focusing on are ophthalmology and muscle disease, along with the further development of some internal compounds in ophthalmology. ... option, while in muscle disease Astellas is working with

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics